Anixa Biosciences, Inc. (ANIX) Cash Flow Statement
Where ANIX’s cash came from and went, FY2025
October 31, 2025 · U.S. dollars- Cash from operations
- −$7.2M
- Capital expenditures
- $0
- Free cash flow
- −$7.2M
- Returned to shareholders
- —
- Change in cash
- −$27,000 cash at year-end $1.2M
Cash from operations
−$7.2M
Investments (net)
+$4.9M
Shares issued
+$2.4M
Other financing
−$98,000
Change in cash
−$27,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
ANIX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ANIX cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$3.4MFY2016 | −$7.2MFY2025 | — | |
| Capital expenditures | $146,521FY2016 | $0FY2025 | −100.0% | |
| Free cash flow | −$3.5MFY2016 | −$7.2MFY2025 | — | |
| Free cash flow margin | −1,176.1%FY2016 | −2,956.7%FY2023 | −1,780.6 pts | |
| Stock-based compensation | $873,561FY2016 | $3.7MFY2025 | +17.3%/yr | |
| Dividends paid | $0FY2017 | $0FY2018 | — | |
| Share buybacks (net) | $0FY2016 | $0FY2025 | — | |
| Capex / revenue | 48.8%FY2016 | 0.0%FY2023 | −48.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ANIX cash flow by activity
OperatingInvestingFinancingChange in cash
ANIX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ANIX cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$11.0M | −$12.7M | −$9.9M | −$13.8M | −$13.1M | −$10.1M | −$11.8M | −$14.2M | −$5.0M | −$5.0M |
| Depreciation & amortization | $36,000 | $37,000 | $46,000 | $42,000 | $59,864 | $90,157 | $466,308 | $343,731 | $368,512 | $358,629 |
| Stock-based compensation | $3.7M | $4.4M | $4.4M | $6.0M | $7.5M | $3.9M | $5.5M | $8.6M | $1.7M | $873,561 |
| Change in working capital | $152,000 | $526,000 | −$1.1M | $485,000 | $78,000 | −$459,009 | $478,423 | $67,702 | $408,240 | −$160,567 |
| Other non-cash items | −$14,000 | $380,000 | $313,000 | $752,000 | $549,136 | $362,825 | $617,171 | $980,776 | −$1.2M | $563,106 |
| Cash from operating activities | −$7.2M | −$7.3M | −$6.2M | −$6.5M | −$4.9M | −$6.2M | −$4.7M | −$4.3M | −$3.8M | −$3.4M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | −$15,791 | −$175,457 | −$38,404 | −$30,188 | −$146,521 |
| Investments (net) | $4.9M | $4.3M | −$5.6M | −$10.7M | −$4.0M | −$290,000 | −$350,000 | $1.5M | −$2.8M | $1.6M |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $42,595 | $0 | $0 | $0 | $45,000 | $0 |
| Cash from investing activities | $4.9M | $4.3M | −$5.6M | −$10.7M | −$3.9M | −$305,791 | −$525,457 | $1.5M | −$2.7M | $1.5M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | — |
| Share repurchases & issuance (net) | $0 | −$6,000 | $0 | $452,000 | — | $9.4M | $5.7M | $2.5M | −$500,000 | $11,800 |
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | −$3.0M | −$3.0M |
| Shares issued | $2.4M | $3.0M | $0 | $0 | $31.1M | $9.3M | $5.5M | $2.5M | $0 | $0 |
| Other financing | −$98,000 | $466,000 | $366,000 | $0 | $440,431 | −$9.3M | −$5.5M | −$2.5M | $10.9M | $3.0M |
| Cash from financing activities | $2.3M | $3.4M | $366,000 | $452,000 | $31.6M | $9.4M | $5.7M | $2.5M | $7.4M | −$2,676 |
| Summary | ||||||||||
| Net change in cash | −$27,000 | $356,000 | −$11.4M | −$16.8M | $22.7M | $2.9M | $435,735 | −$283,484 | $851,051 | −$1.9M |
| Cash at end of period | $1.2M | $1.3M | $915,000 | $12.4M | $29.1M | $6.4M | $3.5M | $3.1M | $3.3M | $2.5M |
| Free cash flow | −$7.2M | −$7.3M | −$6.2M | −$6.5M | −$4.9M | −$6.2M | −$4.9M | −$4.3M | −$3.8M | −$3.5M |
| Free cash flow margin | — | — | −2,956.7% | −0.3% | −964.5% | — | −1,966.8% | −387.6% | −1,055.7% | −1,176.1% |
| Capex / revenue | — | — | 0.0% | 0.0% | 0.0% | — | 70.2% | 3.5% | 8.3% | 48.8% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$2.6M | −$2.5M | −$2.6M | −$2.7M | −$2.3M | −$2.8M | −$3.2M | −$2.9M | −$3.3M | −$3.3M | −$3.3M | −$2.7M |
| Depreciation & amortization | $10,000 | $34,000 | $10,000 | $9,000 | $9,000 | $9,000 | $9,000 | $9,000 | $3,000 | $3,000 | $13,000 | $12,000 |
| Stock-based compensation | $609,000 | $665,000 | $768,000 | $859,000 | $829,000 | $962,000 | $1.0M | $980,000 | $1.1M | $1.1M | $1.1M | $1.2M |
| Change in working capital | $191,000 | $150,000 | −$878,000 | $597,000 | −$82,000 | $140,000 | −$503,000 | $973,000 | −$607,000 | −$607,000 | −$292,000 | −$488,000 |
| Other non-cash items | $45,000 | −$54,000 | $75,000 | −$25,000 | $13,000 | $199,000 | −$228,000 | $24,000 | $182,000 | $182,000 | $152,000 | $71,000 |
| Cash from operating activities | −$1.8M | −$1.7M | −$2.6M | −$1.3M | −$1.5M | −$1.5M | −$2.9M | −$927,000 | −$2.6M | −$2.6M | −$2.3M | −$2.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | −$245,000 | $422,000 | $1.2M | $654,000 | −$833,000 | $2.3M | $2.7M | $867,000 | $2.7M | $556,000 | $129,000 | −$593,000 |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.2M | $0 | $0 |
| Cash from investing activities | −$245,000 | $422,000 | $1.2M | $654,000 | −$833,000 | $2.3M | $2.7M | $867,000 | $2.7M | $2.7M | $129,000 | −$593,000 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | $3,000 | $14,000 | −$17,000 | −$6,000 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $454,000 | $0 | $0 | $0 | $0 | $0 | $833,000 | $2.2M | $0 |
| Other financing | $1.9M | $1.2M | $1.7M | −$104,000 | $1.9M | $4,000 | $0 | $112,000 | $149,000 | −$684,000 | $67,000 | $279,000 |
| Cash from financing activities | $1.9M | $1.2M | $1.7M | $350,000 | $1.9M | $18,000 | −$17,000 | $106,000 | $149,000 | $149,000 | $2.3M | $279,000 |
| Summary | ||||||||||||
| Net change in cash | −$79,000 | −$70,000 | $303,000 | −$251,000 | −$415,000 | $857,000 | −$218,000 | $46,000 | $230,000 | $230,000 | $83,000 | −$2.3M |
| Cash at end of period | $1.4M | $1.5M | $1.5M | $1.2M | $1.5M | $1.9M | $1.1M | $1.3M | $1.2M | $1.2M | $998,000 | $915,000 |
| Free cash flow | −$1.8M | −$1.7M | −$2.6M | −$1.3M | −$1.5M | −$1.5M | −$2.9M | −$927,000 | −$2.6M | −$2.6M | −$2.3M | −$2.0M |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — | — | −1,262.2% |
| Capex / revenue | — | — | — | — | — | — | — | — | — | — | — | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ANIX cash generation
In fiscal 2025 (ended October 31, 2025), Anixa Biosciences generated -$7.2 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$7.2 million. Cash and equivalents fell by $0.0 million over the year.
Related: ANIX income statement, ANIX balance sheet. See the ANIX stock overview for the latest quote and news.
ANIX cash flow FAQ
What is Anixa Biosciences's free cash flow?
Anixa Biosciences's free cash flow was -$7.2 million in fiscal 2025: -$7.2 million of operating cash flow minus $0 of capital expenditures It was -$7.3 million a year earlier..
How much cash does Anixa Biosciences generate from operations?
Anixa Biosciences generated -$7.2 million of cash from operating activities in fiscal 2025.